Table 1
Demographic and Past Medicals History of 19 Patients with Clinical COVID-19 Myocarditis.
| NON-FULMINANT | FULMINANT | OVERALL | |
|---|---|---|---|
| N | 10 | 9 | 19 |
| Age (mean (SD)) | 61.90 (15.84) | 54.56 (20.49) | 58.42 (18.06) |
| Male (n (%)) | 5 (50.0) | 8 (88.9) | 13 (68.4) |
| Body Mass Index (kg/m2) (mean (SD)) [1] | 31.50 (6.48) | 28.76 (5.66) | 30.13 (6.07) |
| Presented with Shortness of Breath (n (%)) | 10 (100.0) | 8 (88.9) | 18 (94.7) |
| Presented with Chest Pain (n (%)) | 4 (40.0) | 1 (11.1) | 5 (26.3) |
| History of Hypertension (n (%)) | 7 (70.0) | 3 (33.3) | 10 (52.6) |
| History of Type 2 Diabetes (n (%)) | 5 (50.0) | 2 (22.2) | 7 (36.8) |
| History of Atrial Fibrillation (n (%)) | 0 (0) | 0 (0) | 0 (0) |
| History of Coronary Artery Disease (n (%)) | 0 (0) | 0 (0) | 0 (0) |
| History of Heart Failure | 0 (0) | 0 (0) | 0 (0) |
| History of Chronic Kidney Disease (n (%)) | 3 (30.0) | 1 (11.1) | 4 (21.1) |
| Supplemental oxygen (n (%)) | |||
| Room air | 3 (30.0) | 1 (11.1) | 4 (21.1) |
| Nasal Canula | 3 (30.0) | 2 (22.2) | 5 (26.3) |
| Nonrebreather | 2 (20.0) | 0 (0.0) | 2 (10.5) |
| Intubation | 2 (20.0) | 6 (66.7) | 8 (42.1) |
| Length of stay in days (mean (SD)) | 10.66 (8.74) | 20.17 (13.60) | 15.17 (12.01) |
| Death (n (%)) | 2 (20.0) | 2 (22.2) | 4 (21.1) |
Table 2
Laboratory findings at time of clinical COVID-19 myocarditis.
| MEAN (SD, NUMBER MISSING) | GEOMETRIC MEAN (NUMBER MISSING) | |||||||
|---|---|---|---|---|---|---|---|---|
| NON-FULMINANT | FULMINANT | OVERALL | P-VALUE | NON-FULMINANT | FULMINANT | OVERALL | P-VALUE | |
| n | 9 | 10 | 19 | 9 | 10 | 19 | ||
| Fold increase in troponin above normal limit | 71 (91.61, 1) | 131 (144.14, 0) | 101 (121.23, 1) | 0.303 | NA | NA | NA | |
| C-reactive Protein (mg/L) | 88 (96.41, 1) | 71 (100.20, 2) | 79 (95.43, 3) | 0.725 | 39 (1) | 45 (2) | 42 (3) | 0.83 |
| Lactate (mmol/L) | 2.76 (0.85, 2) | 2.82 (2.64, 0) | 2.79 (1.95, 2) | 0.952 | 2.64 (2) | 2.14 (0) | 2.36 (2) | 0.45 |
| D-dimer (ng/mL) | 2609 (4533.78, 3) | 4796 (2367.48, 1) | 3775 (3589.89, 4) | 0.253 | 1199 (3) | 4101 (1) | 2311 (4) | 0.028 |
| Ferritin (ng/mL) | 1702 (910.39, 3) | 14176 (17836.06, 1) | 8355 (14174.19, 4) | 0.089 | 1468 (3) | 5660 (1) | 3015 (4) | 0.046 |
| Procalcitonin (ng/mL) | 1.76 (1.40, 4) | 37.74 (72.92, 0) | 23.35 (58.07, 4) | 0.254 | 1.08 (4) | 6.74 (0) | 3.24 (4) | 0.067 |
Table 3
Echocardiographic findings of Clinical COVID-19 Myocarditis.
| NON-FULMINANT | FULMINANT | OVERALL | |
|---|---|---|---|
| N | 10 | 9 | 19 |
| Ejection Fraction (n (%)) | |||
| >50 | 5 (50.0) | 0 (0.0) | 5 (26.3) |
| 40–50 | 1 (10.0) | 5 (55.6) | 6 (31.6) |
| 15–40 | 2 (20.0) | 0 (0.0) | 2 (10.5) |
| Missing data | 2 (20.0) | 4 (44.4) | 6 (31.6) |
| Left Ventricular Systolic Dysfunction (n (%)) | |||
| Left ventricular systolic dysfunction present | 2 (20.0) | 8 (88.9) | 10 (52.6) |
| No left ventricular systolic dysfunction | 6 (60.0) | 0 (0.0) | 6 (31.6) |
| Missing data | 2 (20.0) | 1 (11.1) | 3 (15.8) |
| Left Ventricular Diastolic Dysfunction (n (%)) | |||
| Left ventricular diastolic dysfunction | 1 (10.0) | 0 (0.0) | 1 (5.3) |
| No left ventricular diastolic dysfunction | 7 (70.0) | 7 (77.8) | 14 (73.7) |
| Missing data | 2 (20.0) | 2 (22.2) | 4 (21.1) |
| Pericardial Effusion (n (%)) | |||
| Pericardial effusion | 2 (20.0) | 3 (33.3) | 5 (26.3) |
| No pericardial effusion | 6 (60.0) | 5 (55.6) | 11 (57.9) |
| Missing data | 2 (20.0) | 1 (11.1) | 3 (15.8) |